Anti-TSPAN33 Reference Antibody (Lilly patent anti-TSPAN33)
- 产品详情
- 实验流程
Application
| Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA |
|---|---|
| Primary Accession | Q86UF1 |
| Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1-REM |
| Calculated MW | 31538 Da |
| Target/Specificity | TSPAN33 |
|---|---|
| Expression system | CHO |
For Research Use Only. Not For Use In Diagnostic Procedures.
Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.
| Name | TSPAN33 (HGNC:28743) |
|---|---|
| Synonyms | PEN |
| Function | Part of TspanC8 subgroup, composed of 6 members that interact with the transmembrane metalloprotease ADAM10. This interaction is required for ADAM10 exit from the endoplasmic reticulum and for enzymatic maturation and trafficking to the cell surface as well as substrate specificity. Different TspanC8/ADAM10 complexes have distinct substrates (PubMed:26686862, PubMed:30463011, PubMed:37516108). Plays an important role in normal erythropoiesis (By similarity). It has a role in the differentiation of erythroid progenitors (By similarity). Negatively regulates ligand-induced Notch activity probably by regulating ADAM10 activity (PubMed:26686862). Mediates docking of ADAM10 to zonula adherens by interacting with ADAM10 and, in a PDZD11- dependent manner, with the zonula adherens protein PLEKHA7 (PubMed:30463011). |
| Cellular Location | Cell membrane; Multi-pass membrane protein. Cell junction, adherens junction. Cytoplasm. Note=Is localized to zonula adherens by PLEKHA7 by a PDZD11-dependent interaction |
| Tissue Location | Predominantly expressed in erythroblasts. |
Provided below are standard protocols that you may find useful for product applications.
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。